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Abstract 
 
The aim of this study was to investigate the in vivo effects of estradiol (E2) on myocardial 
metabolism and inducible nitric oxide synthase (iNOS) expression/activity in obese rats. Male 
Wistar rats were fed with a normal or a high fat (HF) diet (42% fat) for 10 weeks. Half of the HF 
fed rats were treated with a single dose of E2 while the other half were placebo-treated. 24h after 
treatment animals were sacrificed. E2 reduced cardiac free fatty acid (FFA) (p<0.05), L-arginine 
(p<0.01), iNOS mRNA (p<0.01), and protein (p<0.05) levels and translocation of the FFA 
transporter (CD36) (p<0.01) to the plasma membrane (PM) in HF fed rats. In contrast, Akt 
phosphorylation at Thr308 (p<0.05) and translocation of the glucose transporter GLUT4 (p<0.05) 
to the PM increased after E2 tretment in HF rats. Our results indicate that E2 acts via PI3K/Akt 
signaling pathway to partially protect myocardial metabolism by attenuating the detrimental 
effects of increased iNOS expression/activity in HF fed rats. 
 
 
 
Key words: estradiol, obesity, myocardial metabolism, cardiovascular diseases, inducible nitric 
oxide synthase 
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List of abbreviations:  
 
Akt, protein kinase B; AS160, Akt substrate of 160 kDa; CD36, fatty acid transporters; E2, 
estradiol; FFA, free fatty acids; GLUT, glucose transporters; HF, high fat; IR, insulin resistance; 
IRS1, insulin receptor substrate-1; L-arg, L-arginine; LDM, low density microsomes; NO, nitric 
oxide; PM, plasma membrane; NOS, NO synthase; iNOS, inducible NOS; NFkB, nuclear factor 
kappa-B; OVX, ovariectomized; PI3K, phosphatidylinositol 3-kinase.  
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1. INTRODUCTION 
One of the leading causes of morbidity and mortality in the developed world is obesity-associated 
cardiovascular disease (Lavie et al. 2014). Substantial evidence implies a direct causation 
between obesity and the increased risk of endothelial dysfunction, hypertension, coronary artery 
disease, heart failure and stroke (Lavie et al. 2009, Lavie et al. 2014). A high fat (HF) diet 
induces body fat accumulation, insulin resistance (IR) and metabolic disorders in animals 
(Buettner et al. 2007, Obradovic et al. 2015b). In our study, we used male rats fed a HF diet as a 
model of obesity-associated IR. In this model the HF diet induces whole body 
IR/hyperinsulinemia, endothelial dysfunction and hypertension (Barnard et al. 1998, Panchal et 
al. 2011, Sudar et al. 2015). Furthermore, we have previously demonstrated using the same male 
model rats, that a HF diet applied for 10 weeks induces obesity accompanied with abnormalities 
such as cardiac hypertrophy, increased serum insulin concentration, whole body IR, 
hyperlipidaemia, hyperleptinemia and inflammation (Obradovic et al. 2015a, Obradovic et al. 
2015b). 
 
Glucose and free fatty acids (FFAs) are the main energy sources in the heart. In cardiac muscle, 
the energy required for contractile function is mainly attained through FFA oxidation (Rider et al. 
2013). In cardiomyocytes transport of glucose and FFAs is mediated via glucose transporters 
(GLUT) and fatty acid transporters (CD36), which migrate between intracellular pools and 
plasma membranes (PM). Estradiol (E2) at physiological concentrations exerts many beneficial 
effects on the heart, including improved vascular function and reduced atherosclerosis (Patten, 
Karas 2006, Romic et al. 2013). These E2-mediated effects include alterations in the activity and 
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expression of many enzymes, including the regulation of nitric oxide synthase (NOS) (Babiker et 
al. 2002). E2 has a direct effect on the heart by influencing lipid metabolism and insulin 
sensitivity (Koricanac et al. 2012). Furthermore, in the same rat model as used in this study we 
have previously reported that in vivo the administration of E2 as a bolus injection reduced cardiac 
hypertrophy, decrease serum total cholesterol and high sensitivity C-reactive protein, and 
realigning of insulin signalling cascade (Obradovic et al. 2015a, Obradovic et al. 2015b). 
 
Nitric oxide (NO) plays an important role in cardiovascular function by regulating relaxation of 
blood vessels and also influencing cardiomyocyte contractility (Moncada, Higgs 1995, Kypreos 
et al. 2014). Endogenously, NO is released as a product during conversion of the amino acid L-
arginine (L-arg) to L-citrulline in a reaction mediated by NOS (Stanimirovic et al. 2015, Sudar-
Milovanovic et al. 2015). The primary source of NO generation in the vascular system is 
endothelial NOS (Rhodes et al. 1995, Kypreos et al. 2014). Overproduction of NO as a result of 
inducible NOS (iNOS) activation leads to reduced myocardial contractility and also has 
detrimental effects to the heart (Ikeda, Shimada 1997). E2 exerts many of its effects in 
cardiomyocytes through activation of the insulin receptor substrate 1 (IRS1), phosphatidylinositol 
3-kinase (PI3K) and protein kinase B (Akt) signalling cascades (Kypreos et al. 2014, Obradovic 
et al. 2014). E2 exerts beneficial effects on the cardiovascular system by reducing nuclear factor 
kappa-B (NFkB), IkB and iNOS expression during ischemia (Karpuzoglu, Ahmed 2006). Under 
normal conditions, E2 also influences energy usage by regulating GLUT and CD36 in heart 
(Gorres et al. 2011, Tepavcevic et al. 2011).  
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In the current study, we show that the PI3K/Akt signalling pathway is altered in obesity 
associated with IR induced by HF feeding in male rats. This likely causes a disruption in the 
translocation of the cardiac transporters GLUT1 and GLUT4 and CD36 to the PM resulting in 
impaired glucose and FFA metabolism, and altered expression/activity of iNOS. We also show 
that the in vivo administration of E2 to obese rats protects against the detrimental effects of 
obesity, preventing the disruption of myocardial glucose and FFA metabolism and reducing the 
impact on iNOS expression/activity. The physiological effects of E2 are very complex and to date 
our knowledge of these in the context of obesity-related cardiac functioning has been limited. The 
results from this study provide important insights into the in vivo cardioprotective effects of E2 in 
obesity, and represent a solid basis for future basic and preclinical studies.  
 
2. MATERIAL AND METHODS  
2.1. Chemicals 
Ether was purchased from Lek (Ljubljana, Slovenia). Luminol, p-coumaric acid and 17ß-
Estradiol (E2; E8875) were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). 
Protease inhibitor (Complete, Ultra Mini, EDTA-free) and phosphatase inhibitor cocktails 
(PhosStop) were obtained from Roche (Mannheim, Germany). The Nitrate/Nitrite Colorimetric 
Assay Kit was obtained from Cayman Chemical (Ann Arbor, MI, USA). Anti phospho-Akt 
(Thr308), and anti total Akt antibodies were obtained from Abcam (Cambridge, UK), while the 
ERα, ERβ, anti-iNOS, anti-NFκB-p65, anti-GLUT1, anti-GLUT4, anti-FAT/CD36 polyclonal 
antibodies, and the mouse monoclonal anti-actin antibody were obtained from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA). Secondary anti-rabbit and anti-mouse IgG 
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horseradish peroxidase-linked antibodies as well as BCIP/NBT (5-bromo-4-chloro-3-indoyl 
phosphate/nitro blue tetrazolium chloride) were obtained from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA, USA). RevertAid H minus First Strand cDNA Synthesis Kit was obtained from 
Thermo Fisher Scientific (Waltham, MA, USA). Primers for rat iNOS and β actin were obtained 
from Metabion (Martinsried, Germany).  Brilliant III SYBR QPCR MasterMix with lowROX 
was purchased from Agilent Technologies (Santa Clara, CA, USA). 
 
2.2. Animals and experimental treatment  
This study was performed on eight weeks old, adult male Wistar rats (150g-200g) bred at the 
Institute of Nuclear Sciences (Vinca, Belgrade). We chose this experimental rat model based on 
our previous results, and literature data (Barnard et al. 1998, Obradovic et al. 2015b). All 
metabolic parameters for these rats in response to the treatments administered in this study are 
detailed in our previous study (Obradovic et al. 2015a). The rats were kept at a 12:12 h, light/dark 
cycle at 22±2°C and divided into two groups: one group (labelled as CONT) was fed for 10 
weeks with a balanced diet for laboratory rats (prepared by Veterinarski zavod Subotica, 
Subotica, Serbia); and a second group (labeled as HF) was fed with a HF diet, a balanced diet for 
laboratory rats enriched with 42% fat. The diet was free of phytoestrogens. Food and water were 
available to rats ad libitum. At the end of the 10th week, half of the rats from the HF fed group 
were treated intraperitoneally with 40 µg/kg of E2 dissolved in 1% ethanol in saline 24 h before 
decapitation and labeled as HF+E2, while the other half of rats from the HF fed group, were at the 
same time injected with the same volume of 1% ethanol in saline. Animals were sacrificed under 
anesthesia. The hearts from each animal were weighed after excision, snap frozen in liquid 
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nitrogen and stored at -80°C until further experiments. Experimental protocols were approved by 
the official Vinca Institute’s Ethical Committee for Experimental Animals. 
 
2.3. Heart lysate preparation 
Heart tissue from each animal was measured (200 mg) and homogenized on ice using an Ultra-
Turrax homogenizer in buffer with protease and phosphatase inhibitor cocktails (10 mM Tris, 
150 mM NaCl, 1 mM EDTA; 10% glycerol, 1% Triton X-100, pH 7.4). Homogenates were 
incubated (1 h, constant rotation at 4°C) and then ultracentrifuged for 20 min, at 4°C at 100,000 × 
g. The Lowry assay (Lowry et al. 1951) was used for measurement of total protein concentration 
in obtained supernatants. Isolated lysates were stored at -80°C and used for further experiments.  
 
2.4. Isolation of plasma membrane (PM) and low-density microsomal (LDM) membrane 
proteins from heart tissue 
Plasma membrane (PM) proteins were isolated from 200 mg of heart tissue from each animal, 
according to Luiken et al. (Luiken et al. 2002). Briefly, heart pieces were incubated for 30 min at 
4°C, in a high-salt solution (20 mM HEPES, 2 M NaCl, and 5 mM sodium azide, pH 7.4) and 
centrifuged for 5 min at 1,000 × g. The pellets were homogenized on ice in TES-buffer (20 mM 
Tris, 250 mM sucrose and 1 mM EDTA, pH 7.4) with protease and phosphatase inhibitor 
cocktail, using Ultra-turrax homogenizer. Homogenates were then centrifuged (5 min at 1,000 × 
g at 4°C) and the pellets were rehomogenized in a TES-buffer and then recombined with the 
supernatant followed by centrifugation (10 min at 100×g at 4°C). Thereafter the supernatants 
were centrifuged (10 min at 5,000 × g at 4°C) and the final pellets (considered as “PM fraction”) 
were resuspended in TES buffer and stored at -80°C for further experiments. Protein 
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concentrations were determined by the Lowry assay (Lowry et al. 1951). Low density 
microsomes (LDM) were isolated from the remaining supernatants by centrifugation (20 min at 
20,000 × g at 4°C). The obtained supernatants were additionally centrifuged for 30 min (at 
48,000 × g at 4°C) and the resulting supernatants were once more centrifuged for 80 min at 
200,000 × g at 4°C. The final pellets were then resuspended in TES buffer and considered as 
“LDM”. 
 
2.5. Measurement of lysate FFA concentration 
The lysate FFA concentrations were determined using a modified version of Duncombe’s 
colorimetric method (Duncombe 1964). Lysate samples (45 µl) were mixed with 225 µl of 
reagent (aqueous solution of Cu(NO3)2·3H2O with triethanolamine (TEA) pH 7.8). Into the 
resulting mixture 1,125 µl of chloroform was added and incubated with intensive shaking for 20 
min and centrifuged for 10 min at 3,000 × g. After removing the top blue-green layer, in the 
lower chloroform phase with extracted FFA, 45 µl 0.2% diethyldithiocarbamate (DDC) has been 
added. After strong shaking, samples were incubated for additional 20 min at room temperature 
and the absorbance was measured at 436 nm on a Lambda 35UV/VIS spectrophotometer (Perkin 
Elmer). The FFA concentration was calculated from a palmitate standard curve and expressed in 
mM. Assays were performed with at least four biological replicates corresponding to each 
treatment. 
 
2.6. SDS-polyacrylamide electrophoresis and Western blotting 
Total heart protein lysates, PM and LDM (50 µg/lane) were separated on SDS-polyacrylamide 
gel (Laemmli 1970) and transferred to nitrocellulose or polyvinylidene difluoride (PVDF) 
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membranes. After protein transfer membranes were blocked with 5% bovine serum albumin and 
probed with primary antibodies directed against ERα, ERβ, iNOS, NFkBp65, non-
phosphorylated Akt, phospho-Akt (Thr308) GLUT1, GLUT4 and CD36. After washing with 
TBST, membranes were incubated with the appropriate secondary anti-rabbit or anti-mouse 
antibodies (dilution 1:2,000) and used for detection with electrochemiluminescence method. As a 
control for equal protein loading, all blots were probed with mouse anti-actin monoclonal 
antibody and appropriate secondary antibody. Image J 1.45s software (National Institutes of 
Health, USA) was used for quantification of signals on membranes. In all cases blots were 
performed on samples prepared from at least three (and in some cases five) rats per treatment 
group. 
 
2.7. Measurement of nitrite/nitate levels in heart lysates 
Nitric oxide (NO) levels in heart lysates were measured indirectly, by determining the 
concentration of nitrate and nitrite as final stable products of NO, using a commercially available 
Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical 780001 IN), according to the 
manufacturer’s protocols. In brief, nitrates were reduced to nitrites by nitrate reductase, and 
nitrites were determined by the method of Griess reagent. Measurements of absorbance at 540 nm 
were performed in an automated microplate reader (Perkin Elmer, Wallac 1420 Victor). NaNO3 
standard curve was used for calculation of the nitrate concentration and results are expressed as 
µM. Assays were performed with at least four biological replicates corresponding to each 
treatment. 
 
2.8. Measurement of L-Arg in heart tissue 
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To measure L-Arg we used spectrophotometric method described by Kowalczuk et al. 
(Kowalczuk et al. 2007). L-Arg was deaminated and converted by ninhydrin into aldehyde. As a 
result of interaction of ninhydrin with ammonia and hydrindantin, a colored compound was 
created, with maximum absorbance at 404 nm. Briefly, heart tissue homogenates with equal 
protein content were diluted with 25mM phosphate buffer (pH 9.0), with 2% ninhydrin reagent 
and heated on 80°C for 15 minutes. After cooling, the L-Arg–ninhydrin derivative was 
determined in a Wallac 1420 Victor microplate reader at 404 nm and L-Arg concentration was 
calculated from a standard curve and expressed in µg/ml. Assays were performed with at least six 
biological replicates corresponding to each treatment. 
 
2.9. Quantitative real-time PCR (qPCR) 
Total RNA was extracted from heart tissue using Trizol reagent (Invitrogen Life Technologies, 
Paisley, GB) according to the procedure recommended by the manufacturer. RNA concentration 
and purity were determined using BioSpec-nano-Spectrophotometer (Shimadzu, USA). 
Degradation of RNA samples was controlled by using 1.2% agarose electrophoresis. Reverse 
transcription of 1 µg of heart RNA, was carried out using a commercially available RevertAid H 
minus First Strand cDNA Synthesis Kit (Thermo Scientific, USA) according to the 
manufacturer’s instructions. The qPCR assay was performed using the 7500 Real-Time PCR 
System (Applied Biosystems) in 96-well reaction plates (MicroAmp Optical, ABI Foster City, 
CA) in 20 µl volume/well, containing 10 µl of reaction mix (Brilliant III) and 10 µl of appropriate 
sample diluted in demineralized water and pairs of primers. The iNOS, and Actb primers were 
designed using Primer Express1 software v2.0 (Applied Biosystems) and purchased from 
Metabion (Martinsried, Germany). To selectively amplify cDNA synthesized from mRNA but 
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not genomic DNA, the primers are designed such that one primer from a pair spans an exon 
junction. Primers for iNOS (GenBank accession number: NM_012611) were 5′-
AGAAGTCCAGCCGCACCAC- 3′ (forward primer) 5′-TGGTTGCCTGGGAAAATCC-3′ 
(reverse primer) with PCR product length of 103 bp and primers for rat β-Actin (GenBank 
accession number: NM_031144) were 5′-CCCTGGCTCCTAGCAC CAT-3′ (forward primer), 
5′-GAGCCACCAATCCA CACAGA-3′ (reverse primer) with PCR product length of 76 bp. The 
thermal cycle conditions for iNOS were 95°C for 4 min followed by 40 cycles that were run for 
15 s at 95° C and for 1 min at 61°C. The level of expression of analyzed iNOS gene was 
standardized against that of the Actb gene detected in the identical sample. All assays were 
performed in triplicate with at least three biological replicates per group. Cycle threshold values 
(Ct) were analyzed and relative quantification of mRNA expression was performed by the 2−∆∆Ct 
method (Livak, Schmittgen 2001). 
 
2.10. Statistical Analysis 
Values gained from experiments are presented as mean ± SEM. Student’s t-test was used to 
evaluate statistical significance. The SPSS program for Windows (SPSS, Chicago, IL, USA) was 
used for statistical analyses. A value of p<0.05 was considered as statistically significant. 
 
3. RESULTS 
3.1. Effect of estradiol on FFA concentratons in heart lysates from HF fed rats 
We have previously shown that the plasma (Obradovic et al. 2015a) and liver lysate FFA 
concentrations (Stanimirovic et al. 2016) are significantly higher in HF fed IR male rats 
compared with controls, and that in vivo E2 treatment has no effect on HF fed male rats plasma 
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FFA concentration (Obradovic et al. 2015a). Here we further examined the effect of a HF diet in 
combination with E2 treatment on the FFA concentration in heart lysates (Figure 1). The results 
show that the FFA concentration is significantly reduced by 25% (p<0.05) in heart tissue lysates 
of E2 treated HF fed rats compared with HF untreated rats (CONT= 0.24±0.03; HF=0.31±0.02; 
HF+E2=0.23±0.02 mM/mg).  
 
3.2. Effect of estradiol on expression of cardiac glucose and fatty acid transporters in HF 
fed rats 
Glucose and fatty acid transporters play an important role in myocardial metabolism. We next 
assessed the expression of the fatty acid transporter, CD36 (Figure 2A) and glucose transporter 
proteins, GLUT1 (Figure 2C) and GLUT4 (Figure 2E) in heart lysates as well as PM and LDM 
fractions. The level of CD36 protein was unchanged in both heart tissue lysates and the LDM 
fraction. In vivo treatment with E2 however significantly decreased (p<0.01) the level of CD36 by 
29% in PM fractions of HF fed animals compared with HF fed untreated rats (CONT=100%; 
HF=73±6%; HF+E2=52±6%). Treatment with E2 did not induce changes in GLUT1 protein 
expression in cardiac lysates, PM or LDM fractions of HF fed rats compared with HF fed 
untreated rats. In contrast, the level of GLUT4 protein was observed to be 27% higher in the PM 
fraction (p<0.05) (CONT=100%; HF=90±4%; HF+E2=114±2%), while it was unchanged in the 
tissue lysate and LDM fraction of E2 treated HF fed rats compared with untreated HF fed rats. 
 
3.3. Effect of estradiol on cardiac NO metabolism in HF fed rats 
Since NO has important roles in the regulation of energy metabolism, insulin sensitivity and 
vasodilatation in obese patients, we further explored the effects of E2 treatment on NO 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
metabolism in the heart of HF fed rats. We first measured the concentration of nitrite/nitate and 
L-Arg in heart tissue lysates. In vivo treatment of HF fed animals with E2 decreased nitrite/nitate 
concentration (p=0.10) but with no statistical significance (Figure 3A). E2 treatment caused a 
significant decrease (p<0.01; Figure 3B) in the cardiac L-Arg concentration in HF fed rats 
compared with HF untreated rats (CONT=65.43±2.77 µg/ml; HF=58.93±0.88 µg/ml; 
HF+E2=54.12±0.64 µg/ml). Obesity and accumulation of lipids could increase expression of 
iNOS, so we further examined whether a HF diet and in vivo E2 treatment of HF fed rats had an 
effect on iNOS gene expression and protein levels. The level of cardiac iNOS mRNA after E2 
treatment (Figure 4A), was decreased by 31% (p<0.01) compared with HF fed untreated animals 
(CONT=0.94±0.05 A.U.; HF=0.99±0.02 A.U.; HF+E2=0.68±0.06 A.U.). Similarly, when HF fed 
rats were treated with E2, cardiac iNOS protein (Figures 4D) was significantly decreased by 41% 
(p<0.05) compared with HF fed rats (CONT=100%; HF=136±14%; HF+E2=80±6%). Since 
NFkB is a transcription factor for iNOS gene, we further examined the effects of a HF diet and in 
vivo E2 treatment on the level of the cardiac NFkB-p65 subunit. The results show that NFkB-p65 
is increased (p=0.08) but was not found to be statistically significant (Figure 4E) in E2 treated 
HF fed rats compared with HF fed untreated rats.  
 
3.4. Effect of estradiol on cardiac Akt-phosphorylation in HF fed rats 
We have previously reported using the same rats (Obradovic et al. 2015a) that E2 given in vivo 
stimulates phosphorylation of Akt at Ser473 in HF fed rats (by 28%, p˂0.05). Since full activation 
of Akt requires both Ser473 and Thr308 to be phosphorylated, we next examined the effects of E2 
on Akt-Thr308 phosphorylation. The results show that in vivo E2 treatment induced a significant 
increase by 40% (p<0.05) in the density ratio between the phospho and total forms of Akt at 
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Thr308 compared with untreated HF fed rats (Figure 5C) (CONT=100%; HF=91±1%; 
HF+E2=127±15%). 
 
3.5. Effect of estradiol on cardiac ERα and ERβ in HF fed rats 
Since effects of E2 are mediated by direct binding to the ER, we have examined the protein levels 
of the cardiac ERα and ERβ in HF fed rats after E2 treatment. The obtained results indicate that 
injected E2 in vivo does not induce any significant changes in the protein levels of ERα and ERβ 
(Figure 6). 
 
4. DISCUSSION 
In this study we examined the protective effects of estradiol on lipid and NO metabolism in the 
heart of rats fed a HF diet. In this study we observed that subjecting rats to a 42% fat (HF) diet 
for 10 weeks increased cardiac FFA concentration, which can be reduced by in vivo treatment 
with E2. It has previously been shown that obesity, accompained with IR shifts myocardial 
metabolism towards usage of FFAs affecting contractile function (Coort et al. 2007). On a 
molecular level, increased concentration of FFA also diminishes cardiac glucose metabolism 
(Coort et al. 2004, Rider et al. 2013). E2 exerts an anti-atherogenic effect influencing lipolysis 
and lipogenesis thus reducing the concentration of lipids in both the blood (Shi et al. 2013) and 
tissues (Hewitt et al. 2004, Jelenik, Roden 2013). Moreover, E2 might decrease synthesis and 
increase FFA oxidation during hyperinsulinemia (Musatov et al. 2007, Gorres et al. 2011).  
 
Uptake of FFA into cardiac cells occurs through several mechanisms, including a protein-
mediated mechanism (Coort et al. 2004, Rider et al. 2013). CD36 is a major contributor to 
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protein-mediated FFA movement into cardiomyocytes (Coort et al. 2004, Rider et al. 2013). 
Lukien et al. reported that cardiomyocytes of obese rats have more CD36 located to the PM 
compared with lean controls (Luiken et al. 2001). E2 positively regulates the expression and the 
translocation of FFA and glucose transporter proteins in rats (Coort et al. 2004, Tepavcevic et al. 
2011, Koricanac et al. 2012). We and others have previously shown that a single injection of E2 
to ovariectomized female rats (OVX) increases the expression of CD36 at the PM of cardiac cells 
in both rats fed normal and fructose-fed diets (Tepavcevic et al. 2011) (Koricanac et al. 2012). 
We now show that administration of E2 to rats fed a HF diet significantly reduced the expression 
of CD36 at the PM. Previous data has shown that leptin treatment reduces the expression of the 
FFA transporter protein CD36, and also reduces the level of CD36 located at the PM (Steinberg 
et al. 2002). Our previous data revealed an increase in the level of serum leptin in obese, leptin-
resistant male rats (Obradovic et al. 2015b) suggesting that the reduced expression of CD36 may 
be a result of increased levels of serum leptin. Although current data indicate that E2 influences 
central leptin sensitivity by enhancing the expression of the leptin receptor (Clegg et al. 2006), 
our leptin-resistant rats were treated with a single dose of E2 which probably was not able to 
reduce long-term increased level of leptin and thus enables CD36 to be translocated to PM.  
 
In obesity and IR, insulin signalling is disrupted, this may lead to a decreased presence of 
GLUT1 and/or GLUT4 (Huisamen et al. 2001) in the PM fraction. In our study, the expression of 
both GLUT1 and GLUT4 transporter proteins was decreased in the heart PM fractions of HF fed 
animals. This is highly relevant when we consider that GLUT1 and GLUT4 are the most 
abundant glucose transporters in the heart. Also, other members of the glucose transporter family 
are detected in the heart, including GLUT3, GLUT8, GLUT10, GLUT11, and GLUT12 (Shao, 
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D., Tian 2015). GLUT1 is responsible for basal glucose metabolism and is mainly located in PM 
under basal conditions (Slot et al. 1991, Montessuit, Lerch 2013). GLUT4 is a major cardiac 
glucose transporter mostly present in the intracellular vesicles. In obese rats with developed IR, 
the utilization of metabolic substrates is disturbed (Coort et al. 2004) and this is likely the result 
of altered GLUT translocation and activity mediated by altered insulin signalling. Indeed, 
previous data have shown that glucose transport is reduced by decreased translocation of GLUT4 
to the PM, but not by reduction of total protein expression (Luiken et al. 2002) in obese animals. 
Results obtained on Zucker obese diabetic rats show significantly lower levels of GLUT4 on the 
sarcolemmal membrane (Huisamen et al. 2001). Imporantly, our data reveal that E2 treatment 
partially restores translocation of GLUT4 (but not GLUT1) to the PM which is likely to have a 
positive influence on myocardial metabolism. Previous studies have shown that in OVX mice fed 
with HF diet E2 treatment improved insulin sensitivity and glucose transport (Riant et al. 2009, 
Zhu et al. 2013). Furthermore, ERα knockout mice have decreased GLUT4 mRNA level in 
skeletal muscle linking the E2 with the regulation of glucose transporters (Barros et al. 2006). The 
observation that E2 influences GLUT4 translocation but not GLUT1 translocation in the heart of 
HF fed rats is interesting. It is likely translocation of these transporters occurs via different 
mechanisms. 
 
In the heart production of NO, catalysed by NOS, depends on the availability of the substrate L-
Arg (Andrew, Mayer 1999). L-Arg deficiency has been strongly implicated in obesity and 
cardiovascular diseases. Cooke et al. (Cooke et al. 1992) reported that local tissue-arginine 
deprivation is known to occur at inflammatory sites. Study on rats with increased level of NO 
derived from iNOS also show reduced level of L-Arg (Zunic et al. 2009). These investigations 
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are in accordance with our results where a diminished cardiac tissue concentration of L-Arg is 
present in HF fed rats, while the concentration of nitrite/nitate was increased. This is probably 
due to increased levels of iNOS as a result of obesity.  
 
The results from our study demonstrate that obesity increases cardiac iNOS gene and protein 
expression in HF fed rats compared to controls, which coincides with increased levels of FFA 
and NO production. These results are consistent with our previous findings (Sudar et al. 2015) as 
well as data gained by others for iNOS expression/activity in states of obesity (de Luca, Olefsky 
2008). Noronha et al. (2005) showed that iNOS expression is significantly increased in aortas of 
obese mice. E2 also displays an anti-inflammatory role in the hearts of obese rats by decreasing 
the level of iNOS gene and protein expression, and NO. Activation of iNOS as a result of OVX 
or inflammation is inhibited by E2 treatment (Maggi et al. 2003). In our study E2 treatment 
diminished iNOS expression which is in accordance with the results of other studies (Maggi et al. 
2003, Nweze et al. 2012), likely as a result of decreased level of lipids measured after E2 
treatment. In accordance with the observed decrease in iNOS expression (and the level of L-Arg), 
a decrease was observed in cardiac nitrate/nitrite concentration following E2 treatment however, 
this was not statistically significant. It is possible that activation of another form of NOS, not 
assessed in the study could, compensate for reduced NO production by iNOS. 
 
Since iNOS expression is regulated primarily by control of gene transcription, a possible 
explanation for increased iNOS expression in HF fed rats may be activation of the transcription 
factor NFkB p65 subunit, which has a binding site on the iNOS gene promotor. Phosphorylation 
of the inhibitor protein NFkB (IkB) is necessary for NFkB to become active, and to translocate to 
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the nucleus. Phosphorylation is mediated by IkB kinase (IKK) which is under the direct 
regulation of Akt (Patten, Karas 2006). E2-induced stabilization of IκBα may be due to inhibition 
of IKK activity and/or inhibition of IκB degradation. Also, E2 has ability to enhance synthesis of 
IκBα and to inhibit NFκB p65 binding to promoters of inflammatory genes such as iNOS (Patten, 
Karas 2006). 
 
In our study a decrease in pAkt(Thr308)/Akt ratio in HF-fed rats is accompanied by a decreased 
level of NFkB p65, while iNOS expression and activity are increased. The PI3K/Akt pathway 
plays an important role in the regulation of glucose metabolism in the heart. It controls 
translocation of GLUT4 from the cytoplasm to the PM and facilitates further uptake together with 
GLUT1 (Huang, Czech 2007). Akt activation leads to phosphorylation and inhibition of the Akt 
substrate of 160 kDa (AS160) which enables GLUT4 to translocate to the PM (Miinea et al. 
2005). Phosphorylation of Akt at both Ser473 and Thr308 is necessary for this process (Shao, J. et 
al. 2000). Beneficial effects of E2 on PI3K/Akt signalling pathway and thus glucose transporters 
have been previously reported (Patten et al. 2004, Tepavcevic et al. 2011, Obradovic et al. 2015a, 
Obradovic et al. 2015b). This is consistent with our observation that following treatement with E2 
to HF fed rats there is an increase in the ratio of pAkt(Thr308)/Akt accompanying increased 
translocation of GLUT4 to the PM. We have previously shown that treatment of HF fed rats with 
estradiol increases phosphorylation of Akt at Ser473 (Obradovic et al. 2015a). In current study no 
differences in ERα or ERβ expression were observed (either as a result of a HF diet or E2 
treatment) suggesting that the E2-mediated effects identified in our study were not the result of 
variations in ER levels. 
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Beside its effect on glucose metabolism, the PI3K/Akt pathway also has proposed roles in 
regulating FFA metabolism and the expression and activity of iNOS acting via NFkB which is a 
downstream target of Akt, where in states of obesity and IR, PI3K/Akt signaling is disrupted 
(Patten, Karas 2006). We have previsouly shown that E2 treatment affects insulin signalling in 
HF fed rats by increasing the expression of both subunits: p85 and p110 of PI3K, and also 
increases association of p85 with IRS1 (Obradovic et al. 2015b). Despite observing a decreased 
level of iNOS in obese rats after E2 treatment, the ratio of pAkt/Akt increased but the level of 
NFkB was not significantly elevated. This suggests that another alternative signalling pathway is 
likely involved in overexpression of iNOS. In order to regulate the inflammatory cascade, E2 
interacts with other transcription factors, besides NFkB, such as AP-1 and STAT. Paech et al. 
(1997) reported that E2 shows opposite influences on NFkB and AP-1 transcription activity, 
depending on whether E2 binds to the ERα or ERβ receptor. This indicates that iNOS expression 
could potentially be regulated via AP-1, and not NFkB as we hypothesized.  
 
In summary, our results indicate that in vivo E2 treatment of HF fed male rats partially restores the 
detrimental effects of a HF diet on myocardial metabolism, whilst influencing the Akt/GLUT 
signalling pathway. Our findings strongly suggest that E2, acts via iNOS, and also regulates 
translocation of the CD36 fatty acid transporter resulting in the accumulation of lipids in heart. In 
clinical trials estrogen has been shown to be a safe and effective therapy in treatment of prostate 
cancer, bone density loss and aggression in men with dementia or traumatic brain injury 
(Kulkarni et al. 2013). Increasing our understanding of the molecular mechanisms determining 
the cardiac action of E2 in males could be a good starting point for future clinical trials on men 
with cardiovascular complications. 
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Figure legends: 
Figure 1. Effects of E2 on FFA concentration in control and HF fed rats. Results are expressed as 
a mean±SEM (*p<0.05; #p<0.05; * indicates significance between CONT and HF or HF+E2; # 
indicates significance between HF and HF+E2).  
 
Figure 2. Effects of E2 on cardiac glucose and lipid metabolism in HF fed rats. (A) Distribution 
of fatty acids transporter CD36 in lysate, plasma membranes (PM) and low density microsomes 
(LDM). (B) Representative western blots of CD36 protein distribution in rat heart lysate, PM and 
LDM. (C) GLUT1 protein distribution in rat heart lysate, PM and LDM. (D) Representative 
western blots of GLUT1 protein distribution in HF rat heart lysate, PM and LDM. (E) GLUT4 
protein distribution in rat heart lysate, PM and LDM. (F) Representative western blots of GLUT4 
protein distribution in rat heart lysate, PM and LDM. Results are expressed as a percentage of the 
value obtained for control and represent the mean±SEM (*p<0.05; **p<0.01; ***p<0.001; 
#p<0.05; * indicates significance between CONT and HF or HF+E2; # indicates significance 
between HF and HF+E2).  
 
Figure 3. Effects of E2 on (A) nitrite/nitrate and (B) L-arginine concentrations in heart lysates of 
control and HF fed rats. Results are presented as the mean±SEM (*p<0.05; **p<0.01; ## p<0.01; 
* indicates significance between CONT and HF or HF+E2; # indicates significance between HF 
and HF+E2).  
 
Figure 4. Regulation of cardiac inducible nitric oxide synthase (iNOS) by E2 in control and HF 
fed rats. (A) iNOS gene expression in HF fed rats. (B and C) Representative Western blots for 
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iNOS and NFkB-p65 protein expression, respectively. (D) iNOS and (E) NFkBp65 protein levels 
in HF fed rats. Results are expressed as a percentage of the value obtained for control and 
represent the mean ±SEM (*p<0.05; #p<0.05; ##p<0.01; * indicates significance between CONT 
and HF or HF+E2; # indicates significance between HF and HF+E2). 
 
Figure 5. Effects of E2 on Akt phosphorylation at Thr308 in control and HF fed rats. (A) Total Akt 
protein expression. (B), Akt phosphorylation level at Thr308. (C) ratio of pAkt (Thr308) and total 
Akt (pAkt/tAkt) in heart of HF rat. (D) Representative western blots of pAkt (Thr308) and total 
Akt protein forms. Results are expressed as a percentage of the value obtained for control and 
represent the mean±SEM (***p<0.001; #p<0.05; * indicates significance between CONT and HF 
or HF+E2; # indicates significance between HF and HF+E2). 
 
Figure 6. Effects of E2 on cardiac ERα and ERβ protein expression in HF fed rats. (A) ERα and 
(C) ERβ protein levels in HF fed rats. (B and D) Representative Western blots for ERα and ERβ 
protein expression, respectively. Results are expressed as a percentage of the value obtained for 
control and represent the mean ± SEM. 
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Highlights: 
• Estradiol treatment influences myocardial glucose and free fatty acid metabolism in 
rats fed a high fat (HF) diet.  
• In vivo estradiol treatment impacts on cardiac iNOS expression/activity in HF fed rats. 
• Estradiol acts via Akt to attenuate the detrimental effects of cardiac iNOS in HF fed 
rats. 
 
